This was the first step though using an experimental lentiviral gene vector that has not been used clinically.
The next step is to use a Adeno-associated viral (AAV) vector that has been used in other medicines on the market. The thought is that by using that it will be easier for the regulators to allow it.
Professor Joost Verhaagen from the Netherlands Institute for Neuroscience is working on creating the AAV now.
What is most exciting is that ISRT are working to take this to the regulators so it can be used in clinical trials.
This was the first step though using an experimental lentiviral gene vector that has not been used clinically.
The next step is to use a Adeno-associated viral (AAV) vector that has been used in other medicines on the market. The thought is that by using that it will be easier for the regulators to allow it.
Professor Joost Verhaagen from the Netherlands Institute for Neuroscience is working on creating the AAV now.
What is most exciting is that ISRT are working to take this to the regulators so it can be used in clinical trials.
They've actually been working on the leaky vector for several years...
The AAV Vector work thats in progress hopes to improve on the lentiviral gene vector so they can stop any leaks. To me leaky doesn't describe the problem well, its more they can't turn every last bit off, but then again I've no idea about science. So quoting what I've been told:
"Using molecular biological techniques they will engineer a regulatable chondroitinase carrying AAV vector. In the first instance, the regulatable AAV vector will carry the gene for luciferase (a protein from the Firefly that gives off light when active), allowing the researchers a way of rapidly quantifying the levels of expression in vivo. Luciferase expression data obtained during four ‘on-off’ cycles will provide information about the inducibility and stability of doxycycline-regulated luciferase expression over time and about the leaky expression. Once regulation of luciferase is optimized in the AAV vector system, the luciferase gene will be replaced with the chondroitinase gene. This inducible chondroitinase AAV vector will then be tested by Professor Bradbury in a rat spinal cord contusion injury model."
If the chase bit doesn't work, at least we will all be able to glow up at night. It will save me crashing my wheelchair when I can't find the light switch :-)
Originally when the large Chase team was formed, Elizabeth Muir was tasked with the job. That's been quite a few years ago. Nobody has yet been successful in getting the gene vector to shut totally off (leaky) with the use of DREADD. Perhaps Joost will get it mastered.
Comment